Boundless Bio Reports First Quarter 2026 Financial Results and Business Highlights
Boundless Bio reported first quarter 2026 financial results highlighting continued enrollment in its KOMODO-1 first-in-human clinical trial of BBI-940, an oral selective kinesin degrader targeting oncogene amplified cancers. The company presented promising preclinical data at AACR 2026 demonstrating robust anti-tumor activity and tumor regressions …